These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18786301)

  • 1. Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: a payer perspective.
    Cohen LJ; Allen JC
    Curr Med Res Opin; 2008 Aug; 24(8):2203-17. PubMed ID: 18786301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of vagus nerve stimulation into a maintenance electroconvulsive therapy regimen: a case study and cost analysis.
    Warnell RL; Elahi N
    J ECT; 2007 Jun; 23(2):114-9. PubMed ID: 17548984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Payer cost savings with endometrial ablation therapy.
    London R; Holzman M; Rubin D; Moffitt B
    Am J Manag Care; 1999 Jul; 5(7):889-97. PubMed ID: 10557409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.
    Helmers SL; Duh MS; Guérin A; Sarda SP; Samuelson TM; Bunker MT; Olin BD; Jackson SD; Faught E
    Eur J Paediatr Neurol; 2012 Sep; 16(5):449-58. PubMed ID: 22261080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression.
    Feldman RL; Dunner DL; Muller JS; Stone DA
    J Med Econ; 2013; 16(1):62-74. PubMed ID: 22954061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients.
    Ben-Menachem E; Hellström K; Verstappen D
    Neurology; 2002 Sep; 59(6 Suppl 4):S44-7. PubMed ID: 12270968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression.
    Rush AJ; Siefert SE
    Exp Neurol; 2009 Sep; 219(1):36-43. PubMed ID: 19397908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression.
    Nierenberg AA; Alpert JE; Gardner-Schuster EE; Seay S; Mischoulon D
    Biol Psychiatry; 2008 Sep; 64(6):455-60. PubMed ID: 18571625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy.
    Purser MF; Mladsi DM; Beckman A; Barion F; Forsey J
    Adv Ther; 2018 Oct; 35(10):1686-1696. PubMed ID: 30143957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VNS and depression: current status and future directions.
    Walsh SP; Kling MA
    Expert Rev Med Devices; 2004 Sep; 1(1):155-60. PubMed ID: 16293018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vagus nerve stimulation acutely alters food craving in adults with depression.
    Bodenlos JS; Kose S; Borckardt JJ; Nahas Z; Shaw D; O'Neil PM; George MS
    Appetite; 2007 Mar; 48(2):145-53. PubMed ID: 17081655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefits and cost effectiveness of vagus nerve stimulation in a long-term treatment of patients with major depression.
    Sperling W; Reulbach U; Kornhuber J
    Pharmacopsychiatry; 2009 May; 42(3):85-8. PubMed ID: 19452375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
    Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
    Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurostimulation therapies for treatment resistant depression: a focus on vagus nerve stimulation and deep brain stimulation.
    Rizvi SJ; Donovan M; Giacobbe P; Placenza F; Rotzinger S; Kennedy SH
    Int Rev Psychiatry; 2011 Oct; 23(5):424-36. PubMed ID: 22200132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
    Joyce AT; Smith P; Khandker R; Melin JM; Singh A
    J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurostimulation therapies in depression: a review of new modalities.
    Marangell LB; Martinez M; Jurdi RA; Zboyan H
    Acta Psychiatr Scand; 2007 Sep; 116(3):174-81. PubMed ID: 17655558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left vagus nerve stimulation for depression: first implantation case post-fDA approval and review of the literature.
    Patwardhan R; Cardenas R; Myers D; Ware P; Nanda A
    J La State Med Soc; 2007; 159(1):38-41. PubMed ID: 17396474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.